Rossari Biotech has corrected 30 percent in last 3 months.
Recommended Articles
View All
This Jadavpur University alumnus has created world’s first energy-saving paint and other amazing stuff
Mar 29, 2023 IST4 Min(s) Read
March F&O Series: Nifty 50 falls over 400 points to mark worst series since September
Mar 29, 2023 IST2 Min(s) Read
Learn how to clear US, UK arrival immigration in 10 seconds from Jet's Sanjiv Kapoor
Mar 29, 2023 IST3 Min(s) Read
UPI transactions new rule from April 1: Users will not be charged due to PPI interchange, clarifies NPCI
Mar 29, 2023 IST3 Min(s) Read
Sunil Chari, Co-founder & MD of Rossari Biotech in an interview to CNBC-TV18 said, margins are likely to increase from Q2FY23 as prices for main raw materials have started declining.
He said the company expects to do Rs 1,600 crore of revenue in FY22 and double the EBITDA in next 2-3 years.
Watch video for more.
